Skip to main content

Table 4 Patient self -evaluation of nausea and vomiting during the 1 st CT cycle (ITT population)

From: Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial

 

Placebo n = 217

Cocculine n = 214

All patients n = 431

p

Nausea frequency

   

0.59†

missing data

16

19

35

 

number of patients evaluable

201

195

396

 

Number of patients with at least 1 episode of nausea, n (%)

164 (81.6)

155 (79.5)

319 (80.6)

 

Nausea severity

0.61*

missing data

16

19

35

 

number of patients evalubale

201

195

396

 

Median (min-max)

0.56 (0–8.5)

0.58 (0–8.3)

0.56 (0–8.5)

 

Vomiting frequency

   

0.56†

missing data

31

19

50

 

number of patients evaluable

186

170

356

 

Number of patients with at least 1 episode of vomiting, n (%)

51 (27.4)

42 (24.7)

93 (26.1)

 

Vomiting severity

missing data

22

25

47

0.44*

number of patients evaluable

195

189

384

 

Median (min-max)

0.00 (0–7.60)

0.00 (0–5.0)

0.00 (0–7.60)

 
  1. *: Mann–Whitney U test †: Person’s chi-square test.